Free tool
Drug Trial Radar: Infectious disease and vaccines
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
50
Active, not recruiting, industry sponsors, Infectious disease and vaccines, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed1,780
50 trials
Showing 1 to 25, recently updated first.
- A Phase 1 Study to Evaluate the Safety and Immunogenicity of GC4006A in Healthy AdultsActive, not recruiting
GC Biopharma CorpIndustry
NCT07728396 · 72 participants · Start Jan 28, 2026 · Primary completion May 2027
Drug: GC4006A; Normal Saline · For: COVID - 19
Sites: Seoul, South Korea
- Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of AgePivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT07516418 · 360 participants · Start Apr 15, 2026 · Primary completion Apr 4, 2027
Drug: H5 Flu Investigational Medical Product (IMP) 1; H5 Flu IMP 2 and 10 more · For: Respiratory Syncytial Virus (RSV); Influenza A(H5N1)
Sites: Griffith, Australia; Herston, Australia; Morayfield, Australia · 6 sites in all
- A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy AdultsActive, not recruiting
ViiV HealthcareGSK (GSK)
NCT06786520 · 69 participants · Start Jan 17, 2025 · Primary completion Mar 8, 2027
Drug: CAB LA; CAB ULA · For: HIV Infections
Sites: Mobile, Alabama; Doral, Florida; Oak Brook, Illinois
- A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSVActive, not recruiting
Immorna Biotherapeutics, Inc.Industry
NCT06564194 · 75 participants · Start Sep 25, 2024 · Primary completion Dec 12, 2024
Drug: JCXH-108 · For: Respiratory Syncytial Virus (RSV); Infectious Disease
Sites: Jupiter, Florida; New Orleans, Louisiana; St Louis, Missouri
- A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT07717840 · 164 participants · Start Jul 8, 2026 · Primary completion Oct 1, 2026
Drug: AZD6489; Licensed RSV vaccine #1 and 1 more · For: RSV Respiratory Syncytial Virus
Sites: Long Beach, California; Rolling Hills Estates, California; Chicago, Illinois · 6 sites in all
- A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus InfectionActive, not recruiting
Suzhou HepaThera Biotech Co., Ltd.Industry
NCT07183306 · 86 participants · Start Dec 30, 2024 · Primary completion Aug 24, 2027
Drug: HT-101; HT-102 · For: Chronic Hepatitis B
Sites: Beijing, China; Xiamen, China; Guangzhou, China · 7 sites in all
- A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06749457 · 242 participants · Start Dec 30, 2024 · Primary completion Mar 8, 2027
Drug: AZD7760 · For: Staphylococcus Aureus
Sites: Huntsville, Alabama; Chula Vista, California; Glendale, California · 40 sites in all
- Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 YearsPivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT07428759 · 122 participants · Start Mar 10, 2026 · Primary completion Nov 19, 2026
Drug: Pn-MAPS30plus · For: Pneumonia, Bacterial
Sites: Norwood, Australia; Camberwell, Australia
- Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older AdultsPivotal-lookingActive, not recruiting
Clover Biopharmaceuticals AUS PtyIndustry
NCT06984094 · 612 participants · Start Jun 18, 2025 · Primary completion Mar 2028
Drug: SCB-1019T; SCB-1022 and 2 more · For: RSV Infection; Human Metapneumovirus Infection; Parainfluenza Infection
Sites: Adelaide, Australia; Melbourne, Australia; Perth, Australia
- A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and InfantPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT07023081 · 200 participants · Start Jun 15, 2025 · Primary completion Jun 10, 2027
Drug: 20vPnC; 13vPnC · For: Pneumococcal Disease
Sites: Nanning, China; Chengxiang, China
- A Study of SN2001 Dose, Safety & Immunogenicity in Healthy AdultsActive, not recruiting
Chimivac INCIndustry
NCT07059403 · 36 participants (planned) · Start Aug 19, 2025 · Primary completion Apr 2027
Drug: SN2001; SN2001 and 1 more · For: Chronic Hepatitis B Infection
Sites: Herston, Australia
- A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT07128615 · 405 participants · Start Sep 4, 2025 · Primary completion Jan 28, 2026
Drug: AZD4117; AZD5315 · For: Influenza A
Sites: Long Beach, California; Rolling Hills Estates, California; Miami Lakes, Florida · 14 sites in all
- Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic MixActive, not recruiting
Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB ChairIndustry
NCT07182838 · 20 participants (planned) · Start Oct 5, 2026 · Primary completion Jun 18, 2027
Drug: HIV Therapeutic Biologic Mix - HIV GP160 plus BCG Vaccine Mix for percutaneous use · For: HIV Infections
Sites: Rockville, Maryland
- A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)Active, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06035497 · 83 participants (planned) · Start Nov 20, 2023 · Primary completion Aug 11, 2026
Drug: BMS-986369 · For: Relapsed or Refractory T-cell Lymphomas
Sites: Anjo-shi, Japan; Nagoya, Japan; Toyohashi, Japan · 40 sites in all
- A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIVPivotal-lookingActive, not recruiting
ViiV HealthcareGSK (GSK)
NCT07053384 · 107 participants · Start Jul 10, 2025 · Primary completion Jan 22, 2027
Drug: VH3810109; Fostemsavir (FTR) and 1 more · For: HIV Infections
Sites: Bakersfield, California; San Diego, California; Ft. Pierce, Florida · 41 sites in all
- A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months of Age Receiving a Single Booster DoseActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT07406334 · 46 participants · Start May 15, 2026 · Primary completion Feb 22, 2027
Drug: Pn-MAPS30plus · For: Pneumonia, Bacterial
Sites: Soweto, South Africa; Pretoria, South Africa
- Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With COVID-19Active, not recruiting
Ever Supreme Bio Technology Co., Ltd.Industry
NCT05501418 · 75 participants (planned) · Start Aug 5, 2020 · Primary completion Dec 31, 2027
Drug: Allogeneic umbilical cord mesenchymal stem cells; Controlled normal saline · For: COVID-19 Infection
Sites: Taichung, Taiwan
- Phase I Clinical Trial of Adsorbed Tetanus VaccineActive, not recruiting
Aimei Vacin BioPharm (Zhejiang) Co., Ltd.Industry
NCT07598890 · 80 participants (planned) · Start May 21, 2026 · Primary completion Jun 20, 2026
Drug: Tetanus Vaccine, Adsorbed; Tetanus Vaccine, Adsorbed · For: Tetanus
Sites: Wuhan, China
- Evaluation of Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 in Severe Coronavirus Disease 2019 PatientsActive, not recruiting
LucasBioIndustry
NCT07709637 · 1 participants · Start Jul 31, 2025 · Primary completion Oct 31, 2026
Drug: LB-DTK-COV19 · For: COVID-19; COVID-19 (SARS-CoV-2 Infection)
Sites: Seoul, South Korea
- Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIVActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT07055451 · 16 participants (planned) · Start Aug 12, 2025 · Primary completion Mar 2028
Drug: B/F/TAF · For: HIV-1-infection
Sites: Los Angeles, California; Atlanta, Georgia; Memphis, Tennessee · 7 sites in all
- Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate VaccinePivotal-lookingActive, not recruiting
CanSino Biologics Inc.Industry
NCT06621654 · 160 participants · Start Nov 15, 2024 · Primary completion Oct 2026
Drug: Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine; Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine and 5 more · For: Haemophilus Influenzae Type B Infection
Sites: Chongqing, China
- Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza VaccinePivotal-lookingActive, not recruiting
Aramis Biotechnologies Inc.Industry
NCT07291635 · 728 participants (planned) · Start Feb 25, 2026 · Primary completion Oct 2026
Drug: Recombinant Influenza vaccine candidate; Commercial Influenza vaccine · For: Influenza
Sites: Halifax, Canada; Montreal, Canada; Pierrefonds, Canada · 7 sites in all
- Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19Active, not recruiting
Rokote Laboratories Finland OyIndustry
NCT07416539 · 20 participants (planned) · Start Feb 10, 2026 · Primary completion Nov 2026
Drug: COVID-19 Vaccines; COVID-19 Vaccines · For: COVID - 19; SARS CoV-2
Sites: Kuopio, Finland
- Efficacy and Safety of the ACC017-Based Antiretroviral Regimen in Treatment-Experienced Adults With HIV-1 Harboring Non-Nucleoside Reverse Transcriptase Inhibitor Resistance MutationsActive, not recruiting
Jiangsu Aidea Pharmaceutical Group Co., Ltd.Industry
NCT07711210 · 12 participants · Start Mar 21, 2025 · Primary completion Jun 30, 2027
Drug: ACC017; Placebo · For: Infection, Human Immunodeficiency Virus
Sites: Shanghai, China
- A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 MonthsPivotal-lookingActive, not recruiting
ModernaTX, Inc.Moderna (MRNA)
NCT05743881 · 186 participants · Start Feb 15, 2023 · Primary completion Aug 31, 2029
Drug: mRNA-1345; mRNA-1365 and 2 more · For: Respiratory Syncytial Virus; Human Metapneumovirus
Sites: Los Angeles, California; Washington D.C., District of Columbia; Melrose Park, Illinois · 17 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.